Abstract
This issue features an article by Lynch, Shivers and colleagues (pages 227–238) which presents a novel, cell-permeable cysteine protease inhibitor, boc-aspartyl(OMe)-fluoromethylketone (boc-Asp-CH2F, abbreviated BAF). This inhibitor is an important new tool available to the research community and may represent a harbinger of a new class of chemicals useful in the treatment of human disease. In order to understand the value of BAF, we need to take a step back and examine the current concepts on the role of apoptosis in human disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wolozin, B. ICE and apoptosis. Mol Psychiatry 2, 184–187 (1997). https://doi.org/10.1038/sj.mp.4000243
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4000243